XML 44 R37.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Organization and Basis of Presentation - Other - (Details) - USD ($) $ in Thousands |  |  |  |  | 3 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | --- | ---
Nov. 21, 2019 | Jul. 22, 2019 | Jun. 27, 2019 | Jun. 19, 2019 | Sep. 30, 2019 | Jun. 30, 2019 | Dec. 31, 2019 | Dec. 31, 2017
Organization and basis of presentation information |  |  |  |  |  |  |  |
Payment of debt assumed in the Avedro Merger |  |  |  |  |  |  | $ 22,496 |
In-process research and development expensed |  |  |  |  | $ 1,500 | $ 2,245 | $ 3,745 | $ 5,320
Licensing Arrangement with Intratus, Inc. |  |  |  |  |  |  |  |
Organization and basis of presentation information |  |  |  |  |  |  |  |
In-process research and development expensed |  | $ 1,500 |  |  |  |  |  |
Cash payments for the acquisition of certain assets |  | $ 1,500 |  |  |  |  |  |
Avedro |  |  |  |  |  |  |  |
Organization and basis of presentation information |  |  |  |  |  |  |  |
Number of shares received in connection with Merger for each share of company owned stock | 0.365 |  |  |  |  |  |  |
Exchange Ratio (as a percent) | 36.50% |  |  |  |  |  |  |
Total Merger Consideration | $ 437,751 |  |  |  |  |  |  |
Fair value of Glaukos common stock issued in the Merger, plus an immaterial amount of cash paid for fractional shares | 406,776 |  |  |  |  |  |  |
Fair value of Replacement Awards attributable to pre-combination services | 30,786 |  |  |  |  |  |  |
Fair value of Glaukos common stock issued to replace certain vested Avedro warrants | 189 |  |  |  |  |  |  |
Payment of debt assumed in the Avedro Merger | (22,500) |  |  |  |  |  |  |
Capitalized property and equipment | $ 1,489 |  |  |  |  |  |  |
DOSE Medical Corporation |  |  |  |  |  |  |  |
Organization and basis of presentation information |  |  |  |  |  |  |  |
Period for U.S. Food and Drug Administration (FDA) approval for additional consideration |  |  |  | 10 years |  |  |  |
Period for EU European Medicines Agency approval for additional consideration |  |  |  | 10 years |  |  |  |
Quarterly royalty rate (as a percent) |  |  |  | 5.00% |  |  |  |
Period for the quarterly royalty rate payments |  |  |  | 10 years |  |  |  |
Cash payments for the acquisition of certain assets of related party |  |  | $ 2,500 | $ 2,500 |  |  |  |
In-process research and development expense |  |  | 2,200 |  |  |  |  |
Capitalized property and equipment |  |  | $ 300 |  |  |  |  |
DOSE Medical Corporation | Minimum |  |  |  |  |  |  |  |
Organization and basis of presentation information |  |  |  |  |  |  |  |
Additional future consideration for U.S. Food and Drug Administration (FDA) approval |  |  |  | 5,000 |  |  |  |
Additional future consideration for European Medicines Agency approval |  |  |  | 1,250 |  |  |  |
Additional future consideration for certain net sales milestones |  |  |  | 7,500 |  |  |  |
Buyout of additional consideration amount |  |  |  | 10,000 |  |  |  |
DOSE Medical Corporation | Maximum |  |  |  |  |  |  |  |
Organization and basis of presentation information |  |  |  |  |  |  |  |
Additional future consideration for U.S. Food and Drug Administration (FDA) approval |  |  |  | 22,500 |  |  |  |
Additional future consideration for European Medicines Agency approval |  |  |  | 2,500 |  |  |  |
Additional future consideration for certain net sales milestones |  |  |  | 20,000 |  |  |  |
Buyout of additional consideration amount |  |  |  | $ 55,000 |  |  |  |

X
- Definition Exchange ratio of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination. + References No definition available. + Details
Name: | gkos_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableExchangeRatio
Namespace Prefix: | gkos_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of equity interests of the acquirer, including instruments or interests issued or issuable for pre-combination services in consideration for the business combination. + References No definition available. + Details
Name: | gkos_BusinessCombinationConsiderationTransferredStockIssuedForReplacementAwardsAttributableToPreCombinationServices
Namespace Prefix: | gkos_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of equity interests of the acquirer, including instruments or interests issued or issuable to replace certain vested acquiree warrants in consideration for the business combination. + References No definition available. + Details
Name: | gkos_BusinessCombinationConsiderationTransferredStockIssuedToReplaceAcquireeWarrants
Namespace Prefix: | gkos_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the amount of consideration paid in a business combination that was expensed as in-process research and development expense. + References No definition available. + Details
Name: | gkos_BusinessCombinationExpensedInProcessResearchAndDevelopmentExpense
Namespace Prefix: | gkos_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The buyout amount of additional future consideration for regulatory approval and certain net sales milestones. + References No definition available. + Details
Name: | gkos_BuyoutOfAdditionalConsiderationAmountForRegulatoryApprovalAndCertainNetSalesMilestones
Namespace Prefix: | gkos_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of additional future consideration for certain net sales milestones. + References No definition available. + Details
Name: | gkos_FutureAdditionalConsiderationAmountForCertainNetSalesMilestones
Namespace Prefix: | gkos_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of additional future consideration for European Medicines Agency approval. + References No definition available. + Details
Name: | gkos_FutureAdditionalConsiderationAmountForEuropeanMedicinesAgencyApproval
Namespace Prefix: | gkos_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of additional future consideration for U.S. Food and Drug Administration (FDA) approval. + References No definition available. + Details
Name: | gkos_FutureAdditionalConsiderationAmountForRegulatoryApproval
Namespace Prefix: | gkos_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The quarterly royalty rate of net sales from DOSE products. + References No definition available. + Details
Name: | gkos_FutureAdditionalConsiderationQuarterlyRoyaltyRateOfNetSales
Namespace Prefix: | gkos_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents the cash outflow for the acquisition of certain assets of non-related party. + References No definition available. + Details
Name: | gkos_PaymentToAcquireAssetNonRelatedParty
Namespace Prefix: | gkos_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the cash outflow for the acquisition of certain assets of a related party. + References No definition available. + Details
Name: | gkos_PaymentToAcquireAssetsOfRelatedParty
Namespace Prefix: | gkos_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The period for regulatory approval from EU European Medicines Agency for additional consideration. + References No definition available. + Details
Name: | gkos_PeriodForEuropeanMedicinesAgencyApprovalForAdditionalConsideration
Namespace Prefix: | gkos_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The period for the quarterly royalty rate payments. + References No definition available. + Details
Name: | gkos_PeriodForQuarterlyRoyaltyRatePayments
Namespace Prefix: | gkos_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The period for regulatory approval from U.S. Food and Drug Administration (FDA) for additional consideration. + References No definition available. + Details
Name: | gkos_PeriodForRegulatoryApprovalForAdditionalConsideration
Namespace Prefix: | gkos_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents repayments of debt acquired in a business combination. + References No definition available. + Details
Name: | gkos_RepaymentsOfAcquiredDebt
Namespace Prefix: | gkos_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The number of shares received in connection with Merger for each share of company owned stock. + References No definition available. + Details
Name: | gkos_SharesReceivedInConnectionWithMergerForEachShareOfCompanyOwnedStock
Namespace Prefix: | gkos_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477 + Details
Name: | us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477 + Details
Name: | us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of property, plant, and equipment recognized as of the acquisition date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 55 -Paragraph 37 -URI http://asc.fasb.org/extlink&oid=116868840&loc=d3e2207-128464 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472 + Details
Name: | us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentInProcess
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_OtherCommitmentsAxis=gkos_LicensingArrangementWithIntratusIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=gkos_AvedroInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=gkos_DoseMedicalCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |